{"nctId":"NCT02592421","briefTitle":"SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2","startDateStruct":{"date":"2015-10-23","type":"ACTUAL"},"conditions":["Type II Diabetes Mellitus"],"count":30,"armGroups":[{"label":"Dapagliflozin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dapagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":["Farxiga"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* T2DM subjects\n* 18 - 70 yrs old\n* BMI = 25-45 kg/m2\n* Must be on a stable dose (more than 3 months) of monotherapy or combination therapy with metformin and/or a sulfonylurea\n* HbA1c \\<10.0%\n* Stable body weight (Â± 3 lbs) over preceding 3 months\n* Do not participate in excessively heavy exercise\n\nExclusion Criteria:\n\n* Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea)\n* Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine \\>1.4 females or \\>1.5 males, or 24-hour urine albumin excretion \\> 300 mg","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Plasma Glucose Concentration","description":"Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose concentration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.7","spread":"3"},{"groupId":"OG001","value":"-17.2","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.9"},{"groupId":"OG001","value":"0.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.3","spread":"3.5"},{"groupId":"OG001","value":"-2.3","spread":"6.1"}]}]}]},{"type":"PRIMARY","title":"Change in Endogenous Glucose Production (EGP)","description":"The change in endogenous glucose production is measured from baseline until the last hour of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.1"},{"groupId":"OG001","value":"-0.56","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"0.12"},{"groupId":"OG001","value":"-1.28","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.09"},{"groupId":"OG001","value":"-0.48","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Plasma Insulin During Measurement of EGP","description":"Measurement of change in plasma insulin concentration during measurement of of EGP from baseline to last hour of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"3","spread":"1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"1"},{"groupId":"OG001","value":"0","spread":"1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"1"},{"groupId":"OG001","value":"0","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Change in Glucagon During EGP Measurement","description":"Measurement of change in glucagon during EGP measurement from baseline to the last hour of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"2"},{"groupId":"OG001","value":"-1","spread":"2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"2"},{"groupId":"OG001","value":"-7","spread":"3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"1"},{"groupId":"OG001","value":"-2","spread":"2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Nausea"]}}}